Pfizer Inc. announced the FDA approved Ibrance (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone… read more.
The National Institute for Health and Care Excellence (NICE) has issued thirteen Technology Appraisal decisions in June 2026, delivering nine positive recommendations, one updated recommendation, and two terminations…. read more.
Eisai Co., Ltd. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has validated the Marketing Authorisation Application (MAA) for taletrectinib for the… read more.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a further nineteen positive recommendations spanning oncology, neurology, infectious disease, dermatology, cardiovascular medicine, diabetes,… read more.
The FDA has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all existing indications of… read more.
NICE (UK): Glycopyrronium bromide (GPB) cream can be used as an option to treat severe primary axillary hyperhidrosis in adults, if lifestyle advice, topical aluminium-based antiperspirants and oral… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine nerandomilast (Jascayd) to treat adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)…. read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has approved a semaglutide injection (Wegovy) to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
